All Oncology News

Oncology Fellows Spotlights Recent Grant and Award Winners

November 6th 2025

Oncology Fellows reports recent hematology/oncology fellows grant and award winners and looks ahead to upcoming grants.

Phase 3 KEYNOTE-905 and IMvigor011 Trials Signal New Standards in MIBC

November 6th 2025

Daniel P. Petrylak, MD, discusses key data in MIBC presented during the 2025 ESMO Congress and previews the 19th Annual New York GU Cancers Congress.

177Lu-edotreotide Displays Efficacy Benefit Across Subgroups in Grade 1/2, SSTR+ GEP-NETs

November 6th 2025

Treatment with 177Lu-edotreotide was linked to improvements in PFS and ORR across subgroups of patients with SSTR-positive GEP-NETs.

CSF1R Blockade With AMB-05X May Improve Tumor Control in ctDNA+ CRC

November 5th 2025

A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.

JAK Inhibitor Selection and Sequencing Strategies Are Key in Myelofibrosis Management

November 5th 2025

Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.

Sneaky Senescent Cells That Resist Cancer Treatment Can Provide Druggable Lung Cancer Target

November 5th 2025

FDA Grants Orphan Drug Designation to M2T-CD33 for Acute Myeloid Leukemia

November 5th 2025

The FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.

HER2DX Could Aid Chemotherapy Decision-Making in HER2+ Early-Stage Breast Cancer

November 5th 2025

HER2DX low-risk scores were associated with improved 10-year RFS and OS outcomes in older patients with HER2-positive early-stage breast cancer.

FDA Adds REMS Guidelines for Pexidartinib in Tenosynovial Giant Cell Tumor

November 5th 2025

The FDA has added REMS guidelines for the use of pexidartinib in tenosynovial giant cell tumor.

Immune-Modulatory and mRNA-Based Cancer Vaccines Could Boost Benefit With ICIs Across Solid Tumors

November 5th 2025

Three experts spotlight key trials from the 2025 ESMO Congress investigating novel cancer vaccines across solid tumors.

GEP-NET–Focused Research Refines Optimal PRRT Use in Well-Differentiated Disease

November 5th 2025

Rohit Thummalapalli, MD, discusses the treatment paradigm for patients with GEP-NETs and the role of Lutetium Lu 177 dotatate across lines of therapy.

Positive KEYNOTE-B96 Data Show Role for Immunotherapy–Based Regimens in PROC

November 4th 2025

Nicoletta Colombo, MD, PhD, discusses clinical implications for integrating immunotherapy into the treatment arsenal for platinum-resistant ovarian cancer.

JAK Inhibitors Expand Treatment Options in Polycythemia Vera and Myelofibrosis

November 4th 2025

Akriti Jain, MD, highlights the evolving role of JAK inhibitors in managing polycythemia vera and myelofibrosis and efforts to optimize treatment sequencing.

FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science

November 4th 2025

The US FDA approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory AML with NPM1 gene mutations.

Vispa-Cel Shows Comparable Efficacy, Durability to Autologous CAR T-Cell Therapy in R/R B-Cell NHL

November 4th 2025

In the phase 1 ANTLER study, vispa-cel demonstrated ORRs of 82% and 86% among patients in the confirmatory and optimized cohorts, respectively.

China’s Center for Drug Evaluation Grants Breakthrough Therapy Designation to Ivonescimab in TNBC

November 4th 2025

Ivonescimab plus chemotherapy has received breakthrough therapy designation as first-line therapy in patients with triple-negative breast cancer.

ADC and CDK4/6 Inhibitor Research Set to Refine TNBC and ER+ Breast Cancer Treatment Strategies

November 4th 2025

Yuan Yuan, MD, PhD, discusses the use of sacituzumab govitecan in TNBC and remaining questions about the use of CDK4/6 inhibitors in ER-positive disease.

Adjuvant Ribociclib Plus AI Therapy Shows More Pronounced iDFS Benefit After 5 Years in HR+, HER2-Negative Early Breast Cancer

November 4th 2025

Sara A. Hurvitz, MD, FACP, unpacks data with adjuvant ribociclib plus endocrine therapy from the 5-year prespecified analysis of the NATALEE trial.

Allogenic CAR T-Cell Therapy CB-011 Drives Responses in R/R Myeloma

November 4th 2025

CB-011 elicited responses in patients with relapsed/refractory multiple myeloma.

Meta Analysis Highlights Benefits of JAK Inhibitors vs BAT in Myelofibrosis

November 3rd 2025

Findings from a meta analysis showed that JAK inhibitors were associated with improved outcomes vs best available therapy in myelofibrosis.